ライフサイエンスコーパス: hyperglycemic clamp

1 hyperinsulinemic-euglycemic clamp and a 2-h hyperglycemic clamp.

2 n littermates (ZCL rats) before and during a hyperglycemic clamp.

3 (pot) or AIR(max), but requires conduct of a hyperglycemic clamp.

4 ons, after a 30-g oral glucose, and during a hyperglycemic clamp.

5 s (1stIR and 2ndIR) were assessed by using a hyperglycemic clamp.

6 /min) during euglycemia and after 6 hours of hyperglycemic clamp.

7 ynthesis and glucose turnover rates during a hyperglycemic clamp.

8 oral glucose challenge and hyperinsulinemic-hyperglycemic clamps.

9 normal-weight AA versus C peers during a 2-h hyperglycemic clamp (12.5 mmol/L) on two occasions: 1) i

10 sensitivity and insulin clearance and a 2-h hyperglycemic clamp (12.5 mmol/l) to assess first- and s

11 A subgroup (n=70) received a 2-h hyperglycemic clamp (+125 mg/dL), and first- and second-

12 fusion of either saline or NA, followed by a hyperglycemic clamp (200 mg/dl).

13 8 micromol x kg(-1) x min(-1)), and during a hyperglycemic clamp, a failure to suppress endogenous gl

14 During the prolonged hyperglycemic clamp, a rise in leptin was observed durin

15 We studied healthy individuals using a hyperglycemic clamp and GLP-1 infusion.

16 beta-Cell function was determined with the hyperglycemic clamp and morphometric analysis of pancrea

17 d-phase insulin responses to a 2-h 13 mmol/l hyperglycemic clamp and the insulin response to a subseq

18 Insulin secretory responses to a hyperglycemic clamp and to a superimposed arginine bolus

19 se-induced insulin secretion both in vivo in hyperglycemic clamps and ex vivo in isolated islets from

20 We performed hyperglycemic clamps and intravenous glucose tolerance t

21 ndirect calorimetry), insulin secretion (2-h hyperglycemic clamp), and body composition (dual-energy

22 in the overnight fasting state and during a hyperglycemic clamp ( approximately 150 mg/dl) in 10 rec

23 history of diabetes) were exposed to 48 h of hyperglycemic clamping (approximately 12 mmol/l).

24 Hyperglycemic clamps (approximately 15 mmol/l) were done

25 dogs underwent a hyperinsulinemic (4x basal) hyperglycemic clamp (arterial blood glucose 146 +/- 2 mg

26 ges, glucose tolerance tests, euglycemic and hyperglycemic clamps, as well as isolated islet and peri

27 A euinsulinemic hyperglycemic clamp at 5, 10, and 15 mmol/l glucose was

28 insulin release in response to i.v. glucose (hyperglycemic clamps at 250 or 350 mg/dl plasma glucose)

29 -cell function was measured with a nine-step hyperglycemic clamp before and 48 h and 14 days after th

30 as the ratio of the OGTT-betaCGS to the 2-h hyperglycemic clamp-betaCGS.

31 rst- and second-phase insulin secretion (2-h hyperglycemic clamp), body composition and abdominal adi

32 travenous glucose tolerance test (IVGTT) and hyperglycemic clamp characterized the insulinotropic eff

33 nd demonstrated higher insulin levels during hyperglycemic clamps compared to saline controls.

34 Under hyperglycemic clamp conditions the transgenic mice had g

35 Hyperglycemic clamps confirmed an increase in insulin se

36 tration curve during the first 12 min of the hyperglycemic clamp (DeltaC-pep[AUC]0-12) was inversely

37 rements, and hyperinsulinemic-euglycemic and hyperglycemic clamp experiments were performed in RLIP76

38 n and two women, BMI 32.6 +/- 0.6) underwent hyperglycemic clamping for 24 h with hourly determinatio

39 During a hyperglycemic clamp, glucose production was suppressed a

40 travenous glucose tolerance test (IVGTT) and hyperglycemic clamp (HGC) in 17 nondiabetic subjects (14

41 1c [HbA1c] 7.8 +/- 1.1%) or hyperinsulinemic-hyperglycemic clamp (HH) (n = 10; 44 +/- 12 years, 8 fem

42 e reabsorption was measured with the stepped hyperglycemic clamp in 15 subjects with type 2 diabetes

43 by applying mathematical modeling during the hyperglycemic clamp in 60 normal glucose tolerance (NGT)

44 ein for 150 min to create a hyperinsulinemic-hyperglycemic clamp in EX-Basal, EX-Sim, and sedentary d

45 In vivo studies using the IVGTT and the hyperglycemic clamp in Sprague Dawley rats demonstrate i

46 e clearance versus insulin levels during the hyperglycemic clamp in the two small groups showed both

47 Stable serum insulin levels during hyperglycemic clamping in patients with NIDDM in the pre

48 ensitivity and secretion were assessed using hyperglycemic clamps in adults and frequently sampled in

49 on GLP-1-stimulated insulin secretion during hyperglycemic clamps in nondiabetic Caucasian individual

50 We studied insulin secretion (by hyperglycemic clamp) in 3-, 9-, and 20-month-old chronic

51 sma C-peptide concentration curve during the hyperglycemic clamp increased by 22 +/- 4 and 23 +/- 4%

52 During the hyperglycemic clamp, lipid infusion enhanced the insulin

53 During the 7 mmol/l hyperglycemic clamp, maintaining a high FFA flux resulte

54 se to glucose was assessed with a +125 mg/dl hyperglycemic clamp on day 3.

55 -1, we performed a five-step (1-h intervals) hyperglycemic clamp on seven heterozygous members (NM) a

56 Intravenous infusion of indinavir during hyperglycemic clamps on rats significantly suppressed th

57 intravenous glucose challenge followed by a hyperglycemic clamp protocol, during which the plasma-in

58 meostasis by hyperinsulinemic-euglycemic and hyperglycemic clamp studies and energy expenditure by in

59 In hyperglycemic clamp studies of Wistar rats, CGP37157 inc

60 Dawley rats (n = 28) were subjected to a 4-h hyperglycemic clamp study (approximately 11 mmol/l).

61 rglycemia on incretin receptor expression, a hyperglycemic clamp study was performed for 96 h with re

62 and free fatty acid (FFA) turnover using the hyperglycemic clamp technique in combination with isotop

63 ealthy subjects (HS) was conducted using the hyperglycemic clamp technique together with duodenal nut

64 A subsample of 81 adolescents underwent the hyperglycemic clamp technique.

65 ciation measuring insulin sensitivity by the hyperglycemic clamp technique.

66 Insulin sensitivity was assessed using the hyperglycemic clamp technique.

67 During the hyperinsulinemic-hyperglycemic clamp that followed either exercise or res

68 active such as during fasting, diabetes, and hyperglycemic clamp, the concentration of GR mRNA increa

69 During the hyperglycemic clamp, there was decreased suppression of

70 Insulin sensitivity during the hyperglycemic clamp was not affected by empagliflozin in

71 Insulin responses during hyperglycemic clamps were augmented by saturated but not

72 ucose infusion rates during hyperinsulinemic-hyperglycemic clamps were increased with GLUT4 overexpre

73 Hyperglycemic clamps were performed in 14 severely obese

74 for hepatic glycogen synthesis and turnover, hyperglycemic clamps were performed with somatostatin [0

75 ulin secretion rates (ISR) measured during a hyperglycemic clamp with either GLP-1 receptor blockade

76 e diet [P-HFF]) underwent a hyperinsulinemic-hyperglycemic clamp with intraportal glucose infusion.

77 ut (Cx36(-/-)) mouse phenotype and performed hyperglycemic clamps with rapid sampling of insulin in C